Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
675 stopped studies mapped to Digestive System Adenocarcinoma and descendants · 93% state a reason
Over the 675 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in…(FIDES-03) | Phase 1 / Phase 2 | terminated | Oct 27, 2020 | Basilea Pharmaceutica | Terminated prematurely for administrative reasons not related to patient safety. | Safety / toxicity |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for… | Phase 2 | terminated | Jan 18, 2023 | Laval University | Recruitment lower than expected and negative results. | Enrollment / accrual |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | — | terminated | Apr 2, 2024 | Paolo Giorgio Arcidiacono, MD | no patients with inclusion criteria | Other (stated, no rule matched) |
| NCT03958669 | Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC(e:Med-HCC-2) | — | terminated | May 22, 2019 | University Hospital Tuebingen | Slow recruitment due to COVID-19 pandemic and several newly approved treatment options | COVID-19 / pandemic |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant…(P2RX7) | N/A | terminated | Nov 18, 2014 | Centre Hospitalier Universitaire de Nice | the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to… | Other (stated, no rule matched) |
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or… | Phase 3 | terminated | May 4, 2016 | Stanford University | Business decision - funding | Funding |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical… | Early Phase 1 | terminated | Jan 23, 2019 | Northwestern University | Lack of funding | Funding |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage… | N/A | withdrawn | Aug 1, 2013 | All India Institute of Medical Sciences | Lack of interest | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | N/A | terminated | Jun 16, 2016 | Shanghai Proton and Heavy Ion Center | For tumor locates away from GI the planned enrolled patient had been completed, but for tumor… | Enrollment / accrual |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | — | terminated | Jan 11, 2022 | Columbia University | Discontinued by Amra Medical due to funding. | Funding |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable… | Phase 1 / Phase 2 | terminated | Mar 8, 2019 | Shanghai Junshi Bioscience Co., Ltd. | Enrollment is over, the study was completed | Enrollment / accrual |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA2) | N/A | withdrawn | Dec 8, 2022 | Techsomed Medical Technologies LTD | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in…(HSL2012-06) | — | terminated | Sep 24, 2012 | Hospital Sirio-Libanes | There was recruted subject | Other (stated, no rule matched) |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for… | Early Phase 1 | withdrawn | Nov 8, 2021 | Mayo Clinic | PI requested | Other (stated, no rule matched) |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or… | Phase 2 | terminated | Mar 3, 2011 | University of Nebraska | Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial | Drug supply |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | N/A | terminated | Jan 22, 2020 | Indiana University | unable to recruit. terminated due to futility | Efficacy / futility |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Phase 2 | terminated | Apr 6, 2018 | Baptist Health South Florida | Slow/poor enrollment | Enrollment / accrual |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission…(PREMETHEP) | N/A | terminated | Jul 28, 2016 | Centre Georges Francois Leclerc | Insufficient recruitment | Enrollment / accrual |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line… | — | terminated | Jun 11, 2020 | Humanity & Health Medical Group Limited | The sponsor withdrawed the sponsorship to the study. | Other (stated, no rule matched) |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 11, 2024source: clinicaltrials